Treosulfan vs. Clofarabine-Based Conditioning
A Phase II Randomized Study to Assess Outcomes With Treosulfan-Based Versus Clofarabine-Based Conditioning in Patients With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML) Undergoing Allogeneic Hematopoietic Cell Transplantation (HCT)
More Information
- Trial Status
- Accepting patients
- Trial Phase
- Phase 2
- Enrollment
- 80 patients (estimated)
- Sponsors
- Fred Hutchinson / University of Washington Cancer Consortium
- Collaborators
- Medexus Pharma, Inc.
- Tags
- Allogeneic Stem Cell Transplant, Antimetabolites, Chemotherapy, Radiation Therapy, Randomization
- Trial Type
- Treatment
- Last Update
- 2 months ago
- SparkCures ID
- 1505
- NCT Identifier
- NCT04994808
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print a patient-friendly report to share with your patient.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.